Control of HIV infection by IFN-α: implications for latency and a cure

Cell Mol Life Sci. 2018 Mar;75(5):775-783. doi: 10.1007/s00018-017-2652-4. Epub 2017 Oct 7.

Abstract

Viral infections, including HIV, trigger the production of type I interferons (IFNs), which in turn, activate a signalling cascade that ultimately culminates with the expression of anti-viral proteins. Mounting evidence suggests that type I IFNs, in particular IFN-α, play a pivotal role in limiting acute HIV infection. Highly active anti-retroviral treatment reduces viral load and increases life expectancy in HIV positive patients; however, it fails to fully eliminate latent HIV reservoirs. To revisit HIV as a curable disease, this article reviews a body of literature that highlights type I IFNs as mediators in the control of HIV infection, with particular focus on the anti-HIV restriction factors induced and/or activated by IFN-α. In addition, we discuss the relevance of type I IFN treatment in the context of HIV latency reversal, novel therapeutic intervention strategies and the potential for full HIV clearance.

Keywords: Anti-viral; Cure; HIV; Interferon; JAK/STAT; Latency.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • HIV / drug effects*
  • HIV / physiology*
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Humans
  • Interferon-alpha / pharmacology
  • Interferon-alpha / therapeutic use*
  • Remission Induction / methods
  • Viral Load / drug effects
  • Virus Latency / drug effects*
  • Virus Latency / physiology

Substances

  • Interferon-alpha